Drugs / AVZO-023
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06998407 | Aug 2025 → Aug 2028 expected | hormone receptor-positive breast cancer | Avenzo Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-05-21 | Avenzo Therapeutics, Inc. | Regulatory Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor avenzotx.com ↗
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced clearance by the U.S. Food and Drug Administration (FDA) of its investigational new drug application (IND) for AVZO-023 (formerly ARTS-023), a potential best-in-class, novel cyclin-dependent kinase 4 (CDK4) selective inhibitor. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AVZO-023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06998407 ↗ |
| Action | Inhibit | “AVZO-023 is an oral selective CDK4 inhibitor” NCT06998407 ↗ |
| Route | Oral | “AVZO-023 is an oral selective CDK4 inhibitor” NCT06998407 ↗ |
| Target | CDK4 | “AVZO-023 is an oral selective CDK4 inhibitor” NCT06998407 ↗ |